MOLECULAR EVOLUTION OF GPCRS

Secretin/secretin receptors

Janice K V Tam, Leo T O Lee, Jun Jin and Billy K C Chow
School of Biological Sciences, The University of Hong Kong, Pokfulam Road, Hong Kong, Hong Kong

Abstract

In mammals, secretin is a 27-amino acid peptide that was first studied in 1902 by Bayliss and Starling from the extracts of the jejunal mucosa for its ability to stimulate pancreatic secretion. To date, secretin has only been identified in tetrapods, with the earliest diverged secretin found in frogs. Despite being the first hormone discovered, secretin's evolutionary origin remains enigmatic, it shows moderate sequence identity in nonmammalian tetrapods but is highly conserved in mammals. Current hypotheses suggest that although secretin has already emerged before the divergence of osteichthyans, it was lost in fish and retained only in land vertebrates. Nevertheless, the cognate receptor of secretin has been identified in both actinopterygian fish (zebrafish) and sarcopterygian fish (lungfish). However, the zebrafish secretin receptor was shown to be nonbioactive. Based on the present information that the earliest diverged bioactive secretin receptor was found in lungfish, and its ability to interact with both vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide potently suggested that secretin receptor was descended from a VPAC-like receptor gene before the Actinopterygii–Sarcopterygii split in the vertebrate lineage. Hence, secretin and secretin receptor have gone through independent evolutionary trajectories despite their concurrent emergence post-2R. A functional secretin–secretin receptor axis has probably emerged in the amphibians. Although the pleiotropic actions of secretin are well documented in the literature, only limited information of its physiological functions in nonmammalian tetrapods have been reported. To decipher the structural and functional divergence of secretin and secretin receptor, functional characterization of the ligand–receptor pair in nonmammals would be the next perspective for investigation.

Key Words

- secretin
- secretin receptor
- evolution
- origin
- divergence

Discovery of secretin: concept of hormones and first physiological function

Secretin was first discovered by Bayliss and Starling in 1902 from the extracts of the jejunal mucosa for its ability to stimulate pancreatic secretion (Bayliss & Starling 1902). They introduced the concept of hormones as chemical messengers released from cells and conveyed by the blood stream to the target organ(s) to stimulate secretion by means of chemical reflex (Modlin & Kidd 2001). ‘Hormone’ was derived from the Greek phrase ‘I arouse to excitement’, and with this novel concept more than a 100 years ago, Bayliss and Starling established the discipline of endocrinology. Since its discovery, it took more than 60 years until SCT peptide was isolated and characterized. Secretin was first purified from the porcine intestine and was found to be a basic 27-amino acid peptide (Jorpes & Mutt 1961, Mutt et al. 1970). Later, SCT peptide or derived sequences from cDNAs was...
characterized from various vertebrates, including chicken (Nilsson et al. 1980), bovine (Carlquist et al. 1981), humans (Carlquist et al. 1985), dog (Shinomura et al. 1987), rat (Kopin et al. 1991), guinea pig (Buscail et al. 1990), rabbit (Gossen et al. 1990), sheep (Bounjoua et al. 1991), Xenopus laevis, and Rana rugulosa (Tam et al. 2011).

Structural evolution of secretin

Secretin as a member of the secretin/glucagon family

Secretin is a member of the secretin/glucagon superfamily which includes a pleiotropic group of brain-gut peptides that share significant structural and conformational homology, with affinity for the secretin/glucagon receptor superfamily of the secretin G protein-coupled receptor (GPCR) family (Ng et al. 2002, Siu et al. 2006, Cardoso et al. 2010). Both sequence and secondary structure of the secretin/glucagon superfamily peptides are highly conserved, in which the latter consists of a random N-terminal structure and a C-terminal alpha helix (Wray et al. 1998, Bourgault et al. 2009).

Currently, ten peptides belonging to the superfamily have been isolated in humans, including pituitary adenylate cyclase-activating polypeptide (PACAP), PACAP-related peptide (PRP), vasoactive intestinal peptide (VIP), peptide histidine isoleucine (PHI)/peptide histidine methionine (PHM), growth hormone-releasing hormone (GHRH), secretin (SCT), glucagon (GCG), glucagon-like peptide 1 (GLP1), glucagon-like peptide 2 (GLP2), and glucose-dependent insulinotropic peptide (or gastric inhibitory polypeptide (GIP)) (Cardoso et al. 2010). In the superfamly, vertebrate secretin demonstrates the lowest sequence conservation. Revealed by sequence and phylogenetic analyses, PACAP; VIP; and GCG are the most conserved members, while PRP; GLP2; and SCT are the most divergent (Cardoso et al. 2010).

Secretin has moderate sequence identity in nonmammalian vertebrates but is highly conserved in mammals

Figure 1A shows the alignment of the mature peptide of secretin from all the vertebrate species hitherto identified and isolated. Turkey and zebra finch predicted sequences were included because of the limited number of nonmammalian tetrapod secretin sequences in the literature. Secretin is highly conserved among the mammalian species (81.5–96.3%) (Fig. 1B). In contrast, when non-mammalian secretins are compared with mammalian secretins, the sequence identity drops to 39.3–51.9% (Fig. 1B). Interestingly, comparison of the sequence identity of secretins in nonmammalian tetrapods reveals that avian secretins only share limited sequence identity with frog secretins (46.4%). It suggests that secretin evolved relatively rapidly along the tetrapod lineage until the divergence of mammals, during which its sequence was under a stringent evolutionary pressure.

As shown in Fig. 1A, SCT peptides maintained well-preserved loci of biological activity in their N-terminal domains. Asp at position 3 is conserved across all the mature SCT peptides and this residue has a role in adenylyl cyclase (AC) stimulation and interacts with the basic residues in the second transmembrane (TM) helix of the secretin GPCRs (Cardoso et al. 2010). Other conserved residues such as His1 and Phe6 are key amino acids in secretin’s GPCR-binding affinity (Gourlet et al. 1991, 1992).
Molecular evolution of secretin

In mammals, the members of the secretin/glucagon superfamily are encoded by six genes (ADCYAPI, GHRH, VIP, GCG, SCT, and GIP) (Fig. 3; Sherwood et al. 2000, Lee et al. 2007). Although it has not been possible to determine the precise timing of the emergence of these genes, they are proposed to have evolved from a primordial exon via exon and gene/chromosome duplications during the chordate radiation (Fig. 3), since they are absent in nonvertebrate genomes including Caenorhabditis elegans, amphioxus, and Ciona (Cardoso et al. 2010, Hwang et al. 2013). Their divergence was postulated to take place after the protostome–deuterostome split from the primordial exon, which was part of an existing gene or gene fragment generated by rounds of gene/genome duplication. Originated from the duplicate exon under different evolutionary pressures, the chordate PACAP-like and glucagon-like subfamilies emerged (Cardoso et al. 2010; Fig. 3).

When did secretin emerge?

The PACAP-like subfamily is hypothesized to begin with a PACAP-like gene more than 650 MYA. From this primordial gene, the ancestral PRP–PACAP was generated by exon duplication. On the basis of the current theory that two rounds of genome duplication (1R/2R) have taken place before the Sarcopterygii–Actinopterygii split (Ohno 1970, Steinke et al. 2006, Ogino et al. 2009), four paralogous genes were generated, in which three of them, PRP-PACAP, PHI-VIP, and GHRH were retained in the genome and passed on along the vertebrate lineage (Cardoso et al. 2010). To add clues to find the origin and divergence time of secretin, we have summarized the comparative chromosomal synteny analyses of secretin previously reported with updates from current genome versions (Fig. 4).

In mammals, SCT is found in all representative species and has a highly conserved genome environment as shown by the neighboring genes DRD4, DEAF1, IRF7, and PNPLA2 (Fig. 4). In avians, SCT has been identified from chicken Gallus gallus, zebra finch Taeniopygia guttata, and turkey Meleagris gallopavo. Although an avian-specific exon duplication that generated the secretin-like peptide has been proposed to have taken place (Wang et al. 2012), the gene environment of secretin is highly syntenic within...
Figure 3
Phylogenetic analysis of the secretin/glucagon hormone precursor superfamily. The tree was generated by maximum likelihood (ML) and plotted by MEGA 5.0. Predicted sequences are marked by asterisk. SCT, secretin precursor; preproGHRH, prepro-growth hormone-releasing hormone; PHI-VIP, peptide histidine isoleucine–vasoactive intestinal peptide precursor; PRP–PACAP, pituitary adenylate cyclase-activating polypeptide (PACAP)-related peptide–PACAP precursor. The proposed primordial exon is represented by a black rectangle.
avians as well as from avians to mammals (Fig. 4). However, using the latest version of the anole lizard genome (AnoCar2.0), a secretin-like sequence could not be identified. The absence of secretin in anoles is likely due to either incomplete genome assembly or the loss of this gene in this species (Hwang et al. 2013). To date, the earliest diverging secretin found is in amphibians represented by the frog species *X. laevis*, *Xenopus tropicalis*, and *R. rugulosa* (Tam et al. 2011). In contrast to the highly syntenic gene environment in mammals and avians, secretin in frogs (represented by *X. tropicalis*) has a relatively less conserved gene order in vicinity. It could be attributed to the incomplete nature of the genome assembly, but it may also represent an earlier chromosomal arrangement of secretin and the genes in proximity. In the Actinopterygii lineage, teleost is the most diverse vertebrate clade (Cardoso et al. 2010). Although, secretin-like sequences have not been found in any available teleost genomes (fugu, medaka, zebrafish, teraodon, and stickleback), a secretin receptor has been identified in zebrafish (Wang et al. 2012). Hence, it has been proposed that secretin does not exist in teleost fish (Tam et al. 2011, Wang et al. 2012) and may be a result of local gene duplications or gene loss that are proposed to have occurred after 2R duplication but before the divergence of teleosts and tetrapods (Hwang et al. 2013). For sarcopterygian fish, lungfish and coelacanth are the only extant species at present (Bailes et al. 2007). Although our group has previously cloned a functional secretin receptor from lungfish *Protopterus dolloi*, we did not find any secretin-like sequence that could be a potential endogenous ligand for this secretin receptor. However, we cannot exclude the possibility that a secretin-like peptide exists in other lungfish species and lobe-finned fish species (e.g., coelacanth).

For agnathans, the first lamprey VIP/PACAP ligands were identified from the Japanese lamprey (Ng et al. 2012).

---

**Figure 4**

Chromosomal locations of SCT genes in various vertebrate species. Neighboring genes of SCT in different vertebrate genomes are shown. Homologous genes in proximity of secretin are linked by straight lines to demonstrate the syntenic gene environment of SCT in the analyzed vertebrate species. Note that sct is not found in zebrafish genome. Versions of genome databases at Ensembl: human (GRCh37), mouse (GRCm38), zebra finch (taeGut3.2.4), chicken (Galgal4), *Xenopus tropicalis* (JGI_4.2), and zebrafish (Zv9).

---

http://jme.endocrinology-journals.org
DOI: 10.1530/JME-13-0259
© 2014 Society for Endocrinology
Published by Bioscientifica Ltd
Printed in Great Britain

Downloaded from Bioscientifica.com at 06/07/2022 10:53:20PM via free access
However, it has been reported that secretin was not found in the sea lamprey, _Petromyzon marinus_, which is an extant primitive vertebrate of the Agnatha clade (Cardoso et al. 2010). Although it could be attributed to the incomplete nature of the genome assembly, suggested by the absence of secretin in both teleosts and sarcopterygian fish species, it is a more plausible explanation that secretin is absent in agnathans. Consistent with this theory, no secretin-like peptide could be identified in extensive genome searches in any early deuterostomes (e.g., urochordates). Although it has been previously reported that secretin-like peptides have been detected by immunohistochemistry in _Ciona intestinalis_, _Styela plicata_, and _Branchiostoma_, secretin-like peptides have never been isolated and sequenced from these animals (Cardoso et al. 2010).

Integrating the current information, we propose that, descended from the primordial exon (Fig. 3), the first ancestral PACAP/secretin-like gene could have appeared in pre- or early vertebrates before the two rounds of whole-genome duplications occurred (Hwang et al. 2013). After a series of chromosomal translocations and/or rearrangements in early vertebrates, this ancestral PACAP/secretin-like gene went through the two rounds of genome duplication before the Sarcopterygii–Actinopterygii split, which generated four copies of this ancestral gene. One of the four copies was eventually established as the _SCT_ gene after local gene duplication and/or loss before the divergence of teleosts and tetrapods (Hwang et al. 2013). Hence, in this proposed evolutionary scheme, secretin is hypothesized to have emerged before the divergence of teleosts and tetrapods but was lost in teleosts and retained only in land vertebrates, explaining why the _SCT_ gene is absent in teleosts as well as sarcopterygian fish.

**Molecular evolution and structural features of secretin receptor**

To understand the evolutionary trajectory of the secretin receptor in the secretin GPCR family, sequences from mammals, chicken, _X. laevis_, lungfish, and zebrafish were analyzed with all the available full-length receptors cloned and obtained from data mining in the PACAP-like receptor subfamily (PAC1, VPAC1, VPAC2, GHRHR, and PRPR) (Fig. 5). On the basis of previous analyses that the receptors for _VIP_, _PACAP_, _GHRHR_, _PRP_, and _SCT_ are descended from a PACAP-like receptor ancestral gene after the initial divergence of the glucagon-like and PACAP-like branches in the secretin GPCR family (Laburthe et al. 1996, Chow et al. 1997, Chan et al. 1998, Cardoso et al. 2010), only the PACAP-like receptors have been included in the analysis (Fig. 5). The phylogenetic tree was generated by ClustalW alignment using the maximum-likelihood (ML) method with the parathyroid hormone receptors (PTHR) as outgroup. The tree grouped the PACAP-like receptors into six major clades (SCTR, GHRHR, PRPR, PAC1, VPAC1, and VPAC2), each of which contains orthologous receptors from different vertebrate species. The monophyly of each receptor clade was strongly supported by the bootstrap values (94–100) (Fig. 5). The overall topology of the tree is in agreement with previous reports (Segre & Goldring 1993, Tam et al. 2011). Phylogenies inferred from the SCTR clade are consistent with the established divergence of vertebrate groups, with lungfish and sarcopterygian SCTRIs most distantly related to the mammalian SCTR sub-branch, demonstrating the gradual divergence of secretin receptors along the Osteichthyes lineage until the emergence of mammalian secretin receptors, during which the receptors were more structurally stabilized.

To reveal the relationship between the structural features and the evolution of SCTR, we summarized the key structural features together with the conservation score in Fig. 6. To minimize potential bias in the conservation score analysis toward mammalian secretin receptors, only one sequence from each vertebrate group was used in the alignment (mammals: human, amphibian: _X. laevis_, avian: chicken, sarcopterygian fish: _P. dolloi_, and teleost: zebrafish).
Alignment of the amino acid sequences of secretin receptors in post-2R vertebrates. The conservation scoring is performed by PRALINE. The score ranged from zero (unconserved) to ten (most conserved) and represented with the color assignment from blue to red. *Homo sapiens* human, *Danio rerio* zebrafish, *Gallus gallus* chicken, *Xenopus laevis* African clawed frog, and *Protopterus dolloi* lungfish.
Ligand-binding domain

The secretin/glucagon superfamily peptides interact in a bivalent mode with their receptors. It is believed that the N-terminal receptor domain is involved in the ligands C-terminus binding, while the juxtamembrane domain and extracellular loops (ECLs) interact with the N-terminus of the ligand. Therefore, the secretinGPCR N-terminal extracellular domain has a defined common pattern of folding for ligand binding. This folding relies on the seven conserved cysteine residues and the specific aspartic acid (Asp53), tryptophan (Trp58), proline (Pro72), glycine (Gly93), and tryptophan (Trp94) residues (position based on the alignment) at the extracellular domain (Furness et al. 2012). These residues are conserved in all the known secretin receptor sequences. Apart from the first cysteine residue (Cys11) that exists as a free residue, the 2nd to 7th residues form three disulfide bonds as follows: 1–4 (Cys25–Cys71), 2–5 (Cys48–Cys89), and 3–6 (Cys57–Cys105). This suggests that the extracellular domain-binding pocket for the ligand secretin was well defined since the emergence of secretin receptor. The short sequence (six residues) insertion and deletion (four residues) in the zebrafish secretin receptor at the ECD may explain its failure to interact with any SCT peptides because the altered extracellular domain cannot recognize the cognate ligand as the other functional secretin receptors (Fig. 6).

Using cysteine-trapping method, together with the data from photoaffinity labeling and molecular modeling, the residues crucial for the interaction of secretin and secretin receptor were predicted. Consistent with previous reports (Segre & Goldring 1993, Dong et al. 2011), the His1 of secretin is known to be essential for binding and biological activity. In this model, the highly conserved Trp284 in TM5 was proposed to interact with His1 of secretin. In addition, Asn278 in the ECL2 has also been proposed to form a hydrogen bond with the secretin residue Asp3 (Dong et al. 2012). This aspartate is highly conserved in the secretin GPCR family and is reported to be critical for the binding affinity and the biological activity of PACAP, VIP, and SCT (Dong et al. 2011). In TM4, Phe268 has been suggested to be in close contact with the Secretin Gly4 (Dong et al. 2012).

Motifs for signal transduction

When stimulated with secretin, all the characterized secretin receptors demonstrate a preferential downstream stimulation toward the cAMP to the intracellular calcium pathway (Siu et al. 2006), with the exception of teleost secretin receptors because no endogenous ligand has been identified (Ng et al. 1999, Tam et al. 2011, Wang et al. 2012). This suggests that the G-protein (Gas) binding domain is well conserved in receptor evolution. Although diverged from the secretin GPCR family, secretin receptor retained the G-protein binding ability as the key regulator of signaling events.

Crucial to maintaining a functional G-protein, the His165 in TM2 and Lys312 and Leu313 in intracellular loop (ICL) 3 are conserved in all the vertebrate secretin receptors. It has been reported that the His165 in TM2 is essential for the surface expression of secretin receptor. Mutation of this His residue (H166A or H166R) in human SCTR decreases the ligand-binding affinity, as well as cAMP response and calcium signaling, thus suggesting the poor surface expression of these mutants (Garcia et al. 2012). Lys312 and Leu313 residues in the ICL3 are important for cAMP signaling in human SCTR (Garcia et al. 2012) and also in other secretin GPCRs (Mathi et al. 1997, Couvaine et al. 2003, Marie et al. 2003).

As shown in Fig. 6, the xCxR motif is well conserved from fish to mammalian secretin receptors. Reported to be important for G-protein functioning (Garcia et al. 2012), mutation of the Arg162 residue in this motif reduces the cAMP responses without abolishing the ligand-binding ability in the rat calcitonin receptor-like receptor (Conner et al. 2006) and the rat glucagon receptor (Cypress et al. 1999). However, this mutation in human SCTR did not impair cAMP signaling, but caused a complete loss of calcium responses (Garcia et al. 2012).

In ICL2, Arg241, and Lys242 have been reported to be critical for the inositol phosphate (IP₃) signaling in many secretin GPCR members (Mathi et al. 1997, Couvaine et al. 2003, Langer et al. 2005). However, mutation analysis showed that this motif did not affect the calcium responses in human SCTR (Garcia et al. 2012). Although Lys242 is conserved in secretin receptors, Arg241 is not conserved across different species, suggesting that this motif is not involved in controlling G-protein functioning in SCTR.

N-linked glycosylation sites

It is well recognized that glycosylation plays an important role in cell surface receptor functions. For human SCTR, various glycosylation inhibitors were shown to reduce the secretin-stimulated cAMP response significantly. Four putative N-glycosylation sites at the extracellular domain (Asn54, Asn82, Asn88, and Asn116) of human SCTR have
been proposed. In the alignment (Fig. 6), only Asn88 is conserved in all secretin receptors. However, mutation of this residue in human SCTR did not have significant impact on the signaling and trafficking of the receptor (Pang et al. 1999). High variation was found for residue Asn82. In agreement with the mutagenesis study, this glycosylation site is not important for receptor functioning. For Asn54, mutation of this residue significantly reduces cAMP response in human SCTR. Mutation of the Asn116 residue gives contrasting findings in human SCTR. Asn-to-Leu mutation enhanced receptor function in cAMP response and Cytosensor assays, but Ser-to-Ala mutation at the same N-glycosylation site significantly decreases the maximal responses in both cAMP and binding assays.

Among all the identified secretin receptors, human secretin could stimulate lungfish and chicken SCTRs but not X. laevis and zebrafish SCTRs. Relating the ligand recognition ability to the glycosylation sites, while lungfish and chicken maintain Asn54 and Asn116 in their sequences, X. laevis and zebrafish SCTRs are substituted with other residues at these sites. Substantiated by this observation, these two positions in the glycosylation site are critical for identifying ligand conformation in the binding process.

Secretin ligand-receptor evolution

Suggested by the comparative evolutionary analyses of all secretin and secretin receptors available at present (Fig. 7), secretin and secretin receptor emerged after the 2R via genome expansion. Since the earliest diverging bioactive secretin receptor was found in the sarcopterygian fish lungfish, its ability to interact with both VIP and PACAP potently suggested that secretin receptor was descended from a VPAC-like receptor before the Actinopterygii–Sarcopterygii split in the vertebrate lineage. Suggested by its role in the modulation of water homeostasis in mammals, the divergence of secretin receptor prior the emergence of tetrapods could be an adaptation to the change from aquatic to terrestrial habitat (Tam et al. 2011). Despite the parallel emergence of secretin and secretin receptor as a consequence of the 2R, they evolved via independent evolutionary trajectories until the divergence of tetrapods. While secretin receptor was retained in teleosts after teleost-specific genome duplication (TSGD), secretin was deleted. Similarly, secretin was lost in the sarcopterygian fish (e.g., lungfish) while secretin receptor was retained in the genome. It was not until the divergence of amphibians that the function of the secretin ligand–receptor pair was first established. Subsequent structural evolvement of the secretin and secretin receptor sequences gradually increased the specificity and affinity of the secretin–secretin receptor axis. Eventually, functions of VIP/PACAP and secretin have become independently regulated in mammals (Tam et al. 2011), as secretin still shows some cross-reactivity with VPAC receptors in avians.

Does secretin have any physiological functions in fish?

In fish species, secretin receptor has been identified in both lobe-finned fish (Sarcopterygii) (lungfish secretin receptor) (Tam et al. 2011) and bony-fish (Actinopterygii) (zebrafish secretin receptor) (Wang et al. 2012) lineages, although endogenous secretin has not been found (Tam et al. 2011, Wang et al. 2012, Hwang et al. 2013). Interestingly, when lungfish SCTR was tested with human and xenopus secretin and other related peptides within the PACAP-like subfamily, it was activated potently in a dose-specific manner by human PACAP and VIP peptides apart from human and xenopus secretin peptides in triggering intracellular cAMP and calcium mobilization (Tam et al. 2011). The zebrafish secretin receptor, however, was not activated by chicken secretin or chicken secretin-like peptides at 1 μM (Wang et al. 2012). Because the zebrafish secretin receptor has not been tested with frog and mammalian SCT peptides, we cannot exclude the possibility that it is a bioactive receptor. However, the absence of secretin suggests that even if the fish secretin receptors are bioactive, they may act as the cognate receptor for peptides (e.g., PACAP and VIP) other than secretin.

Functional emergence of secretin–secretin receptor axis in land vertebrates

The secretin receptor isolated from X. laevis was shown to be highly specific to its endogenous SCT peptide in triggering intracellular cAMP and calcium mobilization (Tam et al. 2011). In a primary pancreatic ductal cell culture prepared from R. rugulosa, xenopus secretin was shown to be able to trigger dose-dependent intracellular cAMP accumulation (Tam et al. 2011). Taking together that the highest co-expression of SCT and SCTR has been detected in X. laevis intestine, it is very likely that secretin has already established its function(s) in the gastrointestinal tract in amphibians.

In avians, unlike the high specificity of secretin and its receptor in frogs, chicken secretin could also activate chicken VPAC1, VAPC2, GHRHR1, GHRHR2, and PAC1 in
addition to secretin receptor (Wang et al., 2012). Also, the secretin-like peptide that only exists in avians is able to activate chicken secretin receptor at a lower potency than secretin but not other structurally related receptors within the secretin GPCR family (Wang et al., 2012). Such difference in ligand–receptor specificity in avians and amphibians could be a result of the avian-specific gene/genome expansion event which generated the secretin-like peptide. With a dual-ligand control mechanism and coordination with other related receptors, we postulate that the physiological functions of secretin have become more diverged but monitored in a more precise manner in avians when compared with amphibians.

Figure 7
Summary of secretin and secretin receptors characterized at present. The hypothetical timing of the two rounds of whole-genome duplications (1R and 2R) (Ogino et al., 2009) and the teleost-specific genome duplication (TSGD) are indicated by a green dot on the phylogeny of the vertebrate lineage. Major events in the evolution of SCT are marked by a yellow diamond and explained with diagrams and description. It is hypothesized that SCT genes were deleted in teleosts and lungfish (Hwang et al., 2013). The cross represents the absence of the genes. Color-filled hexagons represent the presence of a bioactive gene while the white-filled hexagon represents the presence of a gene which may not be bioactive.
Secretin is a neuropeptide in mammals

In humans, there is evidence that secretin could alleviate autistic symptoms (Horvath et al. 1998, Horvath 2000, Kuntz et al. 2004, Toda et al. 2004), suggesting the physiological importance of secretin in the CNS. In rat, secretin has been shown to be involved in water homeostasis by its action in the hypothalamo–neurohypophysial axis (Chu et al. 2009). Under plasma hyperosmolality conditions, secretin is released from the posterior pituitary and it stimulates vasopressin expression and release in the hypothalamus (Chu et al. 2009). It also increases the firing rate of oxytocin neurons dose dependently and exhibits excitatory effects on supraoptic nucleus vasopressin neurons (Velmurugan et al. 2010). In mouse, secretin is involved in the synaptic function, because SCT knockout mice have been reported to have impairment in synaptic plasticity in the hippocampus (Yamagata et al. 2008). However, it is unclear whether secretin exerts any biological functions in the CNS in nonmammalian vertebrates at present. Suggested by the relatively low expression levels of secretin and secretin receptor in frog and chicken, secretin may have limited role in the CNS in nonmammalian vertebrates (Wang et al. 2012).

Secretin serves as a gastrointestinal hormone in both nonmammalian vertebrates and mammals

As mentioned previously, secretin shows bioactivity in frog pancreatic cells (Tam et al. 2011). This principal function of secretin was first demonstrated in dogs. Secretin stimulates the secretion of bicarbonate, water, and electrolytes from the pancreatic ductal epithelium in response to gastric acid and fatty acids in the duodenum (Meyer et al. 1970, Watanabe et al. 1986). In rat, secretin has been demonstrated to potentiate the effect of cholecystokinin in the stimulation of enzyme secretion from the pancreatic acinar cells (Rausch et al. 1985) and promotes pancreatic growth (Solomon et al. 1978, 1983, 1987).

In the duodenum, secretin facilitates the secretion of mucus, bicarbonate, and epidermal growth factor from Brunner’s gland in rat (Olsen et al. 1994). In humans (Dinoso et al. 1973) and dogs (Ramirez & Farrar 1970, Hirose et al. 1986), secretin inhibits the small intestine and colon contraction activity. Moreover, secretin has been demonstrated to inhibit the absorption of water, sodium, and glucose from dog jejunum and rat ileum (Pansu et al. 1980, Hirose et al. 1986), and increase the weight, DNA, and protein content of the rat small intestine (Hoang et al. 1988).

In stomach, secretin acts as an enterogastrone that inhibits gastric acid release and gastric emptying (Valenzuela & Defilippi 1981, Kleibeuker et al. 1984, You & Chey 1987, Raybould & Holzer 1993, Jin et al. 1994). It inhibits pentagastrin-stimulated acid secretion in dogs (Chey et al. 1981), rats (Rhee et al. 1991), and humans (You & Chey 1987). In humans (Dinoso et al. 1969) and dogs (Chey et al. 1981), secretin was reported to delay gastric emptying by inhibiting the gastric motility, in which the contraction force of the antrum is reduced by secretin. Apart from that, secretin was reported to significantly increase endogenous somatostatin in perfused rat (Chung et al. 1994) and dog stomachs (Gerber & Payne 1996). Furthermore, secretin stimulates pepsin secretion in dogs and cats (Magee & Nakajima 1968, Stening et al. 1969). In humans, secretin was reported to increase both pepsin and pepsinogen output of the unstimulated stomach (Walde & Waldum 1981, Waldum et al. 1981).

Secretin in other peripheral organs

Secretin has also been reported to exert biological functions in other peripheral organs including kidney, heart, lung, and the reproductive system. In particular, secretin has been reported to act on the proximal and distal epididymis in an autocrine and paracrine manner to control the secretion of electrolytes and water when secreted by the proximal epididymis in rat (Chow et al. 2004). Interestingly, co-expression of secretin and secretin receptor is also detected in chicken testis, suggesting that secretin may act as an autocrine/paracrine factor involved in the regulation of testis functions (Wang et al. 2012). In ovarioctomized estrogen-primed rats, secretin injection into the preoptic nucleus could increase the circadian rise of luteinizing hormone release (Kimura et al. 1987). In human, secretin has been suggested to be involved in the stimulation of ovulation as a concurrent surge of plasma secretin and serum estradiol has been observed (Holst et al. 1989a), and it inhibits prolactin release during follicular and luteal phases of the menstrual cycle (Holst et al. 1991). Also, the plasma secretin level is significantly increased from week 28 to 36 during pregnancy in human (Holst et al. 1989b). Hence, apart from the digestive system, secretin probably plays a role in the reproductive system in nonmammalian vertebrates. It would be interesting to investigate whether secretin would be involved in both the male and female reproductive systems in frogs and chickens because they utilize a different reproductive approach from mammals.
Although the moderate sequence conservation of secretin in nonmammalian vertebrates may implicate rapid functional evolution, it is possible that secretin first emerged as a gastrointestinal hormone in early vertebrates, and via the modulation of the ligand–receptor specificity, secretin becomes a pleiotropic hormone in mammals, exhibiting a wide spectrum of functions in different parts of the body.

**Conclusion and future perspectives**

Secretin diverged prior the Actinopterygii–Sarcopterygii split and is descended from the primordial exon that produced four paralogous genes as a result of the genome expansion (2R) in the vertebrate lineage. Its cognate receptor is proposed to have descended from VPAC-like receptors in parallel with secretin, resulting in having a copy in both lungfish and zebrafish, although their endogenous secretins were lost. Secretin and secretin receptor have gone through independent evolutionary processes despite their parallel emergence. A functional secretin–secretin receptor axis was first established with the divergence of amphibians. At present, although the physiological functions of mammalian secretin are well studied, the information on the bioactivity and functions of secretin in nonmammalian tetrapods are limited. To understand the structural and functional evolution of secretin, secretin functions in nonmammals should be further explored and studied in different vertebrate species (teleosts, lungfish, frogs, and chicken) for the next step.

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review.

**Funding**

This work was supported by the Hong Kong government grants, HKU6/CRF/11G and GRF764812M to B K C C and Committee on Research and Conference Grants (CRCG) 20101159013 to L T O L.

**Acknowledgements**

The authors thank Dr Christopher Binny for the editing of the manuscript.

**References**


Chey WY, Kim MS, Lee KY & Chang TM 1981 Secretin is an enterogastrone in the dog. American Journal of Physiology 240 G239–G244.


Cypess AM, Unson CG, Wu CR & Sakmar TP 1999 Two cytoplasmic loops of the glugacon receptor are required to elevate cAMP or intracellular calcium. Journal of Biological Chemistry 274 19455–19464. (doi:10.1074/jbc.274.27.19455)


Ng SY, Lee LT & Chow BK 2012 Receptor oligomerization: from early evidence to current understanding in class B GPCRs. Frontiers in Endocrinology 3 175.


Valenzuela JE & Delfilippi C 1981 Inhibition of gastric emptying in humans by secretion, the octapeptide of cholecystokinin, and intraduodenal fat. Gastroenterology 81 589–902.


Watanabe S, Chey WY, Lee KY & Chang TM 1986 Secretin is released by digestive products of fat in dogs. Gastroenterology 90 1008–1017.


You CH & Chey WY 1987 Secretin is an enterogastrone in humans. Digestive Diseases and Sciences 32 466–471. (doi:10.1007/BF01296028)

Received in final form 12 March 2014
Accepted 21 March 2014